Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | TSHR | P16473 | 2/20 | 0.62 |
| ▸ | BLM | P54132 | 2/20 | 0.62 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | MPO | P05164 | 1/20 | 0.62 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.62 |
| ▸ | TNF | P01375 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.51 |
| ▸ | HTR2C | P28335 | 1/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18029211 | 1.00 | MAPT (0.62) | MAPTKMT2AKDM4ELMNATSHR | |
| SCHEMBL1594834 | 1.00 | MAPT (0.62) | MAPTKMT2AKDM4ELMNATSHR | |
| SCHEMBL28419283 | 0.89 | KMT2A (0.59) | MAPTKMT2AKDM4ELMNATSHR | |
| SCHEMBL28419284 | 0.89 | KMT2A (0.59) | MAPTKMT2AKDM4ELMNATSHR | |
| SCHEMBL19846987 | 0.88 | SOS2 (0.48) | MAPTKMT2AKDM4ELMNATSHR | |
| SCHEMBL1460650 | 0.86 | MAPT (0.69) | MAPTKMT2AKDM4ELMNATSHR | |
| SCHEMBL18029110 | 0.86 | MAPT (0.69) | MAPTKMT2AKDM4ELMNATSHR | |
| SCHEMBL1460647 | 0.86 | MAPT (0.69) | MAPTKMT2AKDM4ELMNATSHR | |
| SCHEMBL18029204 | 0.84 | MAPT (0.63) | MAPTKMT2AKDM4ELMNATSHR | |
| SCHEMBL20816072 | 0.84 | MAPT (0.63) | MAPTKMT2AKDM4ELMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 289 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200247858-A1 | AGENTS MODULATING BETA-CATENIN FUNCTIONS AND METHODS THEREOF | FOG PHARMACEUTICALS, INC. (US) | 2020-08-06 | — | — | US | claimed |
| EP-3678683-A2 | AGENTS MODULATING BETA-CATENIN FUNCTIONS AND METHODS THEREOF | Fog Pharmaceuticals, Inc. (US) | 2020-07-15 | — | — | EP | claimed |
| CN-111372942-A | β -catenin function modulating agents and methods thereof | 弗格制药有限公司 | 2020-07-03 | — | — | CN | claimed |
| CN-111118048-A | Use of chimeric phenylalanyl-tRNA synthetases/tRNAs | 浙江大学 | 2020-05-08 | — | — | CN | claimed |
| WO-2019051327-A2 | AGENTS MODULATING BETA-CATENIN FUNCTIONS AND METHODS THEREOF | FOG PHARMACEUTICALS, INC. (US) | 2019-03-14 | — | — | WO | claimed |
| US-5658885-A | OLIGOPEPTIDES; ANTICOAGULANTS; ENZYME INHIBITORS; THROMBIN | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-08-19 | — | — | US | claimed |
| US-20260071243-A1 | BIOLOGICAL PRODUCTION OF TRYPTOPHAN-DERIVED PRODUCTS | UNIV TEXAS (US) | 2026-03-12 | — | — | US | disclosed |
| US-20260002147-A1 | ENGINEERED SYNTHASE FOR PRODUCTION OF TRYPTOPHAN DERIVATIVES AND INTRANSIGENT SUBSTRATES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2026-01-01 | — | — | US | disclosed |
| US-20250367300-A1 | Nanomaterial and Methods of Use Thereof | UNIVERSITY OF CONNECTICUT (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250354108-A1 | METHODS FOR PRODUCING MONOTERPENE INDOLE ALKALOIDS | UNIV DANMARKS TEKNISKE (DK) | 2025-11-20 | — | — | US | disclosed |
| US-20250320253-A1 | TRANSMEMBRANE PEPTIDIC ANTAGONISTS OF PLEXIN-A1 AND THEIR THERAPEUTIC USES | UNIV STRASBOURG (FR) | 2025-10-16 | — | — | US | disclosed |
| US-20250302762-A1 | NANOMATERIAL DELIVERY VEHICLE AND METHOD OF USE THEREOF | UNIVERSITY OF CONNECTICUT (US) | 2025-10-02 | — | — | US | disclosed |
| US-12385029-B2 | Engineered synthase for production of tryptophan derivatives and intransigent substrates | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2025-08-12 | — | — | US | disclosed |
| WO-2001064678-A2 | INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-09-07 | — | — | WO | disclosed |
| WO-2001040262-A1 | ALPHA-KETOAMIDE INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-06-07 | — | — | WO | disclosed |
| WO-2001002424-A2 | PEPTIDE BORONIC ACID INHIBITORS OF HEPATITIS C VIRUS PROTEASE | DU PONT PHARMACEUTICALS COMPANY (US) | 2001-01-11 | — | — | WO | disclosed |
| WO-2000068413-A1 | HALO- OR HYDROXY-SUBSTITUTED NOCATHIACIN ANTIBIOTICS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-11-16 | — | — | WO | disclosed |
| US-5658885-A | OLIGOPEPTIDES; ANTICOAGULANTS; ENZYME INHIBITORS; THROMBIN | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-08-19 | — | — | US | disclosed |
| EP-0787010-A1 | AMIDINO AND GUANIDINO SUBSTITUTED INHIBITORS OF TRYPSIN-LIKE ENZYMES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-08-06 | — | — | EP | disclosed |
| WO-1996012499-A1 | AMIDINO AND GUANIDINO SUBSTITUTED INHIBITORS OF TRYPSIN-LIKE ENZYMES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250367300-A1 | Nanomaterial and Methods of Use Thereof | EPCAM, CD47, JAK2 | MAPT 1013/4885KMT2A 718/4885KDM4E 848/4885 |
| US-20200247858-A1 | AGENTS MODULATING BETA-CATENIN FUNCTIONS AND METHODS THEREOF | CTNNB1, CTNNBL1, CTNNA1 | MAPT 3674/4885KMT2A 3036/4885KDM4E 1902/4885 |
| US-20250302762-A1 | NANOMATERIAL DELIVERY VEHICLE AND METHOD OF USE THEREOF | JAK2, JAK1, CHMP4B | MAPT 605/4885KMT2A 1471/4885KDM4E 2142/4885 |
| US-12385029-B2 | Engineered synthase for production of tryptophan derivatives and intransigent substrates | WARS1, TPH1, TPH2 | MAPT 2121/4885KMT2A 1560/4885KDM4E 2269/4885 |
| US-20260071243-A1 | BIOLOGICAL PRODUCTION OF TRYPTOPHAN-DERIVED PRODUCTS | TPH1, TPH2, SLC6A4 | MAPT 1647/4885KMT2A 1283/4885KDM4E 3485/4885 |
| US-20260002147-A1 | ENGINEERED SYNTHASE FOR PRODUCTION OF TRYPTOPHAN DERIVATIVES AND INTRANSIGENT SUBSTRATES | INMT, TPH1, TPH2 | MAPT 1835/4885KMT2A 1052/4885KDM4E 1227/4885 |
| US-20250354108-A1 | METHODS FOR PRODUCING MONOTERPENE INDOLE ALKALOIDS | INMT, KARS1, MIA3 | MAPT 3008/4885KMT2A 445/4885KDM4E 2243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.